Abstract
Abstract
Background
Insurances in high-income countries (HIC) often contract with private community pharmacies to dispense medicines to outpatients. In contrast, dispensing of medicines in low- and middle-income countries (LMICs) often lacks such contractual arrangements. Furthermore, many LMICs lack sufficient investment in supply chains and financial and human resources to guarantee stock levels and services at public medicine-dispensing institutions. Countries striving to achieve universal health coverage (UHC) can, in principle, incorporate retail pharmacies into their supply chains to expand access to essential medicines (EMs). The objectives of this paper are (a) to identify and analyze key considerations, opportunities and challenges for public payers when contracting out the supply and dispensing of medicines to retail pharmacies and (b) to provide examples of strategies and policies to address these challenges.
Methods
A targeted literature strategy was used to conduct this scoping review. We created an analytical framework of key dimensions: (1) governance (including medicine and pharmacy regulation); (2) contracting (3) reimbursement; (4) medicine affordability (5) equitable access; and (6) quality of care (including ‘patient-centered’ pharmaceutical care). Using this framework, we selected a mix of three HIC and four LMIC case studies and analyzed the opportunities and challenges encountered when contracting retail pharmacies.
Results
From this analysis, we identified a set of opportunities and challenges that should be considered by public payers considering public–private contracting: (1) balancing business viability with medicine affordability; (2) incentivizing equitable access to medicines; (3) ensuring quality of care and delivery of services; (4) ensuring product quality; (5) task-sharing from primary care providers to pharmacies and (6) securing human resources and related capacity constraints to ensure sustainability of the contract.
Conclusion
Public–private partnerships offer opportunities to improve access to EMs. Nonetheless, managing these agreements is complex and is influenced by a variety of factors. For effective contractual partnerships, a systems approach is needed in which business, industry and regulatory contexts are considered in tandem with the health system. Special attention should be devoted to rapidly changing health contexts and systems, such as changes in patient preferences and market developments brought about by the COVID-19 pandemic.
Funder
The Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program
Reference67 articles.
1. Garcia MM, Azevedo PS, Mirelman A, Safatle LP, Iunes R, Bennie MC, Godman B, Guerra Junior AA. Funding and service organization to achieve universal health coverage for medicines: an economic evaluation of the best investment and service organization for the brazilian scenario. Front Pharmacol. 2020;11:370. https://doi.org/10.3389/fphar.2020.00370.
2. Rankin J, Gremillion M, Eghan K. Management of medicines benefit programs in low-and middle- income settings-adapting approaches from high-income countries [Internet]. Management Sciences for Health, Accenture; 2015 [cited October 2022]. Available from: https://marketbookshelf.com/wp-content/uploads/2017/12/pbm_manual_complete.pdf
3. Agrawal P, Barton I, Bianco RD, Hovig D, Sarley D, Yadav P. Moving medicine, moving minds: helping developing countries overcome barriers to outsourcing health commodity distribution to boost supply chain performance and strengthen health systems. Glob Health Sci Pract. 2016;4(3):359.
4. Gonsalves L, Martin Hilber A, Wyss K, Say L. Potentials and pitfalls of including pharmacies as youth-friendly contraception providers in low- and middle-income countries. BMJ Sex Reprod Health. 2021;47(1):6.
5. USAID Global Health Supply Chain Program. 2019 Contraceptive Security Indicators Report. USAID Global Health Supply Chain Program; 2020.